KALA BIO (KALA) FY Conference August 13, 2025 01:00 PM ET Speaker0Good afternoon, and thank you for joining the HC Wainwright fifth Annual Ophthalmology Virtual Conference. For this panel discussion, I'd like to welcome the following panelists to share with us their view on multiple novel drugs for front of the eye indications. Mister Mark Wong, chief executive officer and chairman of the board of HARO. Doctor King Brazil, chief medical officer of Kala Bio, doctor Gary Jacob, chief executive officer of Okio ...

KALA BIO (KALA) closed the last trading session at $7.44, gaining 35.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13 indicates a 74.7% upside potential.The average comprises three short-term price targets ranging from a low of $12.00 to a high of $15.00, with a standard deviation of $1.73. While the lowest estimate indicates an increase of 61.3% from the current price level, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1167 Massachusetts Avenue Arlington, MA 02476 (Address of principal executive offices) (Zip Code) (781) 996-5252 (Registrant's telephone number, including area code) | Securities regi ...

Exhibit 99.1 KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update KALA's innovative pipeline is based on its proprietary mesenchymal stem cell secretome (MSC- S) platform. KALA believes the multifactorial mechanism of action of its MSC-S platform technology may enable it to generate product candidates for a range of rare, ocular diseases and is evaluating the potential development of this technology for multiple rare, front- and back- of-the-eye diseases. KALA's lead product ...

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of t ...

Core Insights - New analyst coverage is essential in navigating heightened economic uncertainty, providing updated insights into company fundamentals and risk exposures [2][3] - Recent initiations of coverage on companies like KALA BIO, Graham Corporation, Arq, and Hawkins reflect the growing need for sharper analysis amid inflationary pressures and weakening demand [3][10] Analyst Coverage Importance - Analysts possess specialized knowledge that offers critical insights into a company's financial health, growth potential, and industry trends, which are often difficult for individual investors to acquire independently [4] - New coverage typically indicates a higher investor inclination towards a stock, as it suggests that the company holds potential value [5][7] Value Creation by Analysts - Analysts create value for companies by initiating coverage, acting as intermediaries with extensive access to relevant data, which helps mitigate inefficiencies in the market [6] - Stocks chosen for new coverage usually reflect a positive outlook envisioned by analysts, often leading to more favorable ratings compared to continuously covered stocks [7][8] Market Impact of New Coverage - New analyst coverage can lead to immediate stock price volatility, with positive ratings attracting bullish sentiment and driving share prices higher, while negative ratings may trigger sell-offs [9] - Favorable coverage from multiple analysts can enhance investor confidence, leading to sustained upward momentum in stock valuations [9] Recent Stock Performances - KALA BIO shares increased by 96.1% over the past three months, with a narrowing loss per share estimate for 2025 [10][15] - Graham Corporation shares rose by 75.2% in the same period, with an increasing EPS estimate for fiscal 2026 [10][16] - Arq shares gained 57%, with an unchanged EPS estimate indicating improvement from the previous year's loss [10][17] - Hawkins shares saw a 25.6% increase, despite an unchanged EPS estimate indicating a year-over-year decline [10][18] Screening Criteria for Investment - Stocks with increased analyst coverage and improving average ratings are prioritized, alongside other parameters such as price and average daily volume [12][13]

-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the completion of patient ...

KALA BIO (KALA) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Go ahead and start. Welcome, everyone. First of all, I wanted to thank the Jefferies team for inviting us to provide an ups oh, I need to find the way. An update on Kala and remind everyone there will be likely some forward looking statements. So, Kala is a leader, in the emerging field of mesenchymal stem cell secretomes, and our focus is on rare ophthalmic diseases. We have an ongoing pivotal trial with our lead product, KPI o one two, for ...

ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025. To ac ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA BIO, Inc. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or other jurisdict ...